“This is a welcome additional treatment option for this patient population and reinforces our goal of delivering new options to patients living with difficult-to-treat cancers," said Owen Smith, the general manager of Bristol Myers Squibb Australia and New Zealand.
Expanded listing for Bristol Myers Squibb's PD-1 to include bladder cancer
July 2, 2025 Latest NewsBioPharma
Latest Video
New Stories
-
There is an ideology behind our funding systems, and it's the greatest barrier to change
March 11, 2026 - - Latest News -
New patient-led tool launched in Canberra to transform pain communication
March 10, 2026 - - Latest News -
Leader appointed to drive landmark Sydney biomedical hub toward global health breakthroughs
March 10, 2026 - -
New digital partnership expands access to clinical guidance for Australian healthcare professionals
March 10, 2026 - - Latest News -
Self injection option offers new flexibility for Australians living with Myasthenia Gravis
March 10, 2026 - - Latest News -
CSL expands US manufacturing with $1.5bn investment to boost plasma therapy production
March 10, 2026 - - Latest News -
Labor’s FoI backdown is a welcome victory for transparency and accountability
March 10, 2026 - - Latest News

